Lipocine Inc.: directors' dealings · United States · SEC (Form 4)

About Lipocine Inc.

Lipocine Inc. (NASDAQ: LPCN) is a U.S.-listed biopharmaceutical company headquartered in Salt Lake City, Utah, United States. The company was founded in 1997 and has built its business around proprietary oral drug-delivery technology designed to improve the way therapeutics are administered, particularly for products that benefit from a more convenient, patient-friendly oral profile. For investors, Lipocine should be viewed as a small-cap biotech with meaningful execution risk, where value creation depends on clinical development, regulatory milestones, and partnership-driven monetization rather than a broad commercial platform. ([ir.lipocine.com](https://ir.lipocine.com/overview)) Lipocine’s core strategy is to leverage its formulation and delivery expertise to create differentiated oral products aimed at large markets with unmet medical needs. Its most advanced and commercially relevant asset is TLANDO, an oral testosterone replacement therapy approved by the U.S. FDA for adult men with certain forms of hypogonadism. TLANDO is the company’s key marketed/potentially marketed franchise and has been central to a series of licensing and distribution agreements that extend the asset beyond the U.S. market. ([ir.lipocine.com](https://ir.lipocine.com/overview)) The broader pipeline remains development-stage. Lipocine’s lead R&D program is LPCN 1154, an oral brexanolone formulation in Phase 3 for postpartum depression. Additional candidates include LPCN 2101 and LPCN 2203 in neurology-focused opportunities, LPCN 2401 for obesity-related body-composition management, and LPCN 1148 and LPCN 1144, which target liver disease and metabolic-liver indications such as cirrhosis and MASH. This diversified pipeline gives the company multiple shots on goal, but it also means clinical readouts, regulatory interactions, and capital requirements are still major investor considerations. ([ir.lipocine.com](https://ir.lipocine.com/2025-05-06-Lipocine-Announces-License-and-Supply-Agreement-for-TLANDO-R-in-Brazil?utm_source=openai)) From a competitive standpoint, Lipocine is not trying to compete as a large integrated pharmaceutical company. Instead, it occupies a niche position as a formulation specialist focused on converting therapeutically valuable compounds into oral products with improved usability. That makes its competitive set partly direct, partly indirect: it competes against other oral formulations, but also against established injectable or alternative therapies in the same disease areas. The company’s operating footprint remains centered in the United States, although recent commercialization agreements have broadened its geographic reach into Brazil, Canada, South Korea, and GCC markets. ([stocktitan.net](https://www.stocktitan.net/sec-filings/LPCN/10-k-lipocine-inc-files-annual-report-cf3a12072666.html?utm_source=openai)) Recent catalysts have been especially important. In 2025, Lipocine advanced its Phase 3 postpartum-depression study for LPCN 1154, announced a Canadian New Drug Submission for TLANDO through its partner, and signed a license and supply agreement with Aché to commercialize TLANDO in Brazil. The company also issued multiple financial and operational updates through 2025 and into 2026, underscoring an active catalyst calendar. For French, Belgian, and Swiss investors, Lipocine is best understood as a speculative NASDAQ biotech with upside tied to clinical outcomes, partnership execution, and the company’s ability to maintain financing flexibility. ([ir.lipocine.com](https://ir.lipocine.com/overview))